US Edition
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
- Novo Nordisk announced mostly mild-to-moderate side effects and beneficial blood sugar outcomes from phase 3 CagriSema trials at the ADA in Chicago on June 22, 2025.
- These announcements followed the REDEFINE 1 and 2 studies, 68-week phase 3 trials evaluating once-weekly CagriSema, a combination of semaglutide and cagrilintide, in adults with overweight or obesity with or without type 2 diabetes.
- The REDEFINE 1 study involved approximately 3,400 participants who did not have diabetes but faced weight-related health issues, whereas REDEFINE 2 included around 1,200 individuals with type 2 diabetes who were treated with either CagriSema or a placebo.
- Participants lost up to 20.4% body weight in REDEFINE 1 and 13.7% in REDEFINE 2, increasing to 22.7% and 15.7% respectively with full treatment adherence, alongside low discontinuation rates of 6%.
- These findings indicate new possibilities for managing obesity and type 2 diabetes, although negative investor reactions led to a drop in Novo Nordisk’s stock price; the company is also planning additional clinical trials and regulatory submissions before the end of the year.
Insights by Ground AI
Does this summary seem wrong?
68 Articles
68 Articles
All
Left
5
Center
25
Right
3
Novo Nordisk's Weight-loss Drug Trial and Eli Lilly's Promising Obesity Treatment
Novo Nordisk's Weight-loss Drug Trial and Eli Lilly's Promising Obesity Treatment Pharmaceutical giant Novo Nordisk has revealed that its latest weight-loss drug, CagriSema, exhibited mostly mild-to-moderate side effects during trials, accompanied by beneficial blood sugar outcomes. Despite these positive results, investor sentiment remained negatively swayed, reflected in the downturn of Novo's share prices after the announcement.Meanwhile, riv…
·India
Read Full Article
Coverage Details
Total News Sources68
Leaning Left5Leaning Right3Center25Last UpdatedBias Distribution76% Center
Bias Distribution
- 76% of the sources are Center
76% Center
15%
C 76%
Factuality
To view factuality data please Upgrade to Premium
